Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced Cancer - Concepedia

Concepedia

Publication | Closed Access

Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced Cancer

167

Citations

26

References

2006

Year

Michael J. Robertson, James W. Mier, Theodore F. Logan, Michael Atkins, Henry Koon, Kevin M. Koch, Steven J. Kathman, Lini Pandite, Coreen Oei, Lyndon C. Kirby,

Clinical Cancer Research

Abstract

rhIL-18 can be safely given in biologically active doses to patients with advanced cancer. A maximum tolerated dose of rhIL-18 was not determined. Further clinical studies of rhIL-18 are warranted.

References

	Year	Citations

Page 1